Loomis Sayles & Co. L P Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Loomis Sayles & Co. L P decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,899 shares of the biotechnology company's stock after selling 5,724 shares during the quarter. Loomis Sayles & Co. L P owned 0.29% of Ascendis Pharma A/S worth $24,629,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Legato Capital Management LLC grew its holdings in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after purchasing an additional 134 shares during the last quarter. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 328 shares during the last quarter.

Remove Ads

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded up $1.95 during mid-day trading on Wednesday, hitting $153.38. The company's stock had a trading volume of 179,773 shares, compared to its average volume of 466,291. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The stock's fifty day simple moving average is $145.13 and its two-hundred day simple moving average is $137.86. The firm has a market capitalization of $9.31 billion, a P/E ratio of -21.55 and a beta of 0.61.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ASND. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. Evercore ISI boosted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price on the stock. Finally, The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Ascendis Pharma A/S currently has an average rating of "Moderate Buy" and a consensus target price of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.